Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:19 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas
NCT02700022 · UNC Lineberger Comprehensive Cancer Center · PHASE1 · terminated · last registry update 2017-11-20 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of funding” | – | Registry record, UNC Lineberger Comprehensive Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against AURKA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2018-11-15Results posted on the registry: Millennium Pharmaceuticals, Inc., Alisertib (NCT02214147)
- 2018-11-09Results posted on the registry: Merck Sharp & Dohme LLC, MK-5108 + docetaxel (NCT00543387)
- 2018-10-31Results posted on the registry: Millennium Pharmaceuticals, Inc., [^14C]-alisertib + alisertib (NCT01714947)
- 2018-10-11Results posted on the registry: Massachusetts General Hospital, Alisertib + Cytarabine (NCT02560025)
- 2018-07-31Results posted on the registry: Millennium Pharmaceuticals, Inc., Alisertib + Pralatrexate (NCT01482962)
- 2018-07-27Also stopped (withdrawn): Eric Bernicker, MD, Brentuximab Vedotin + Alsertib (NCT02780011)
- 2018-06-06Results posted on the registry: Ohio State University Comprehensive Cancer Center, alisertib + rituximab (NCT01812005)
- 2018-06-06Also stopped (terminated): Ohio State University Comprehensive Cancer Center, alisertib + rituximab (NCT01812005)
- 2018-06-04Results posted on the registry: Millennium Pharmaceuticals, Inc., Alisertib + Paclitaxel (NCT01091428)
- 2018-05-17Also stopped (terminated): Fox Chase Cancer Center, MLN8237 and Erlotinib (NCT01471964)
- 2018-05-11Results posted on the registry: Millennium Pharmaceuticals, Inc., Alisertib (NCT00830518)
- 2018-03-27Results posted on the registry: Millennium Pharmaceuticals, Inc., Alisertib (NCT00853307)
- 2018-03-27Results posted on the registry: Millennium Pharmaceuticals, Inc., Alisertib (NCT00807495)
- 2018-03-27Results posted on the registry: Millennium Pharmaceuticals, Inc., Alisertib (MLN8237) + Rituximab (NCT01397825)
- 2017-12-06Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Alisertib + Abiraterone acetate (NCT01848067)
- 2017-11-29Results posted on the registry: Weill Medical College of Cornell University, MLN8237 (NCT01799278)
- 2017-11-07Results posted on the registry: University Health Network, Toronto, ENMD-2076 (NCT01719744)
- 2017-06-05Results posted on the registry: Children's Oncology Group, Alisertib (NCT01154816)
- 2017-03-27Also stopped (withdrawn): M.D. Anderson Cancer Center, Alisertib + TAK-228 (NCT02812056)
- 2016-12-28Results posted on the registry: National Cancer Institute (NCI), Alisertib (NCT01653028)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision